Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2020 | Therapeutic options in multiple sclerosis

Celia Oreja-Guevara • 24 May 2020
EAN 2020
Multiple Sclerosis and Related Disorders Antibodies Interferon-beta Ocrelizumab

Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, outlines the current therapeutic options in multiple sclerosis and discusses the unmet needs in the field. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Celia Oreja-Guevara

2:01
Characteristics of NMOSD relapses
Celia Oreja-Guevara • 2 Jul 2023
2:58
OCT-angiography: assessing optic nerve vascularization in MS patients
Celia Oreja-Guevara • 2 Jul 2023
1:59
New recommendations on MS treatment and holistic patient care
Celia Oreja-Guevara • 2 Jul 2023
1:05
Therapeutic strategies targeting smoldering neuroinflammation in MS
Celia Oreja-Guevara • 2 Jul 2023

Related Videos

1:59
Exciting remyelination research in MS: cell therapy and neuromodulation
Giancarlo Comi • 23 Mar 2024
2:30
The potential of wearables for continuous activity monitoring in MS
Giancarlo Comi • 23 Mar 2024
3:19
Is MS progressive from onset? Challenging the classical understanding of progression
Giancarlo Comi • 23 Mar 2024
1:50
BTK inhibitors for MS treatment: what do the recent trial readouts mean for the field?
Giancarlo Comi • 23 Mar 2024
The content of VJNeurology is intended for healthcare professionals